ArticleBlood advances2024

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.

Brian T Hill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.